| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-1505 | |
| Phytochemical name or plant extracts | Sesamol | |
| PMID | 34325508 | |
| Literature evidence | Sesamol may be a safe and effective option for clinical adjuvant therapy in patients with ERα-negative breast cancer. | |
| IUPAC name | 1,3-benzodioxol-5-ol | |
| Phytochemicals’ class or type of plant extracts | Phenolic compound | |
| Source of phytochemicals or plant Extracts | Sesamum indicum | |
| Geographical availability | Assam, Bangladesh, India, West Himalaya | |
| Plant parts | Seeds | |
| Other cancers | Breast cancer | |
| Target gene or protein | pS2, GREB1, DNMT3A, DNMT3B, miR-370-3p | |
| Gene or Protein evidence | Sesamol induced ER? functional re-expression followed by upregulation of its downstream pS2 and GREB1 genes in ER?-negative breast carcinoma. Mechanistically, sesamol induced ESR1 gene promoter demethylation by downregulating the expression of the DNA methyltransferases DNMT3A and DNMT3B, without affecting DNMT1. Moreover, the non-coding RNA miR-370-3p directly targeted DNMT3A and DNMT3B mRNA, and its expression increased upon treatment with sesamol. | |
| Target pathways | NA | |
| IC50 | NA | |
| Potency | In summary, our study revealed that sesamol epigenetically induced ER? reactivation via miR-370-3p-mediated downregulation of DNMT3A and DNMT3B in ER-negative breast carcinoma models. These findings enhance the current knowledge on the biological properties of sesamol and show that this agent may be helpful for the clinical adjuvant treatment of patients with ER-negative breast cancer. | |
| Cell line/ mice model | MDA-MB-231, HUVEC and Hs-578T cells. | |
| Additional information | In addition, miR-370-3p mimics downregulated DNMT3A and DNMT3B expression but not DNMT1, these effects were accompanied by reactivation of ER, pS2, and GREB1 | |
| PubChem ID | 68289 | |
| Additional PMIDs | NA | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:675971-1 | |
| Safety | NA |